

Data Sharing Statement

Article Info	http://dx.doi.org/10.21037/atm-21-934	
Item	Question	Authors' Response (place “-” if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	CLA can effectively weaken osteoclast promotion, osteogenic inhibition, and oxidative damage caused by UVB. Combination treatment of UVB and CLA exerts an osteoprotective effect on ovariectomized osteoporotic rats and stimulates osteogenesis. The molecular mechanism of this interaction requires further investigation.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	None.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Scholars interested in Osteoporosis.
8	For what type of analysis or purpose?	To analyze the osteoprotective effects of UVB and conjugated linoleic acid (CLA) in Osteoporosis.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: chenliangspine@163.com .
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.